Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL), Agile Therapeutics (AGRX) and TG Therapeutics (TGTX)


There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ocular Therapeutix (OCUL), Agile Therapeutics (AGRX) and TG Therapeutics (TGTX) with bullish sentiments.

Ocular Therapeutix (OCUL)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Ocular Therapeutix, with a price target of $12. The company’s shares closed yesterday at $3.72, close to its 52-week low of $3.46.

According to TipRanks.com, Selvaraju ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -12.3% and a 31.4% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.

Ocular Therapeutix has an analyst consensus of Strong Buy, with a price target consensus of $14.60.

See today’s analyst top recommended stocks >>

Agile Therapeutics (AGRX)

H.C. Wainwright analyst Oren Livnat reiterated a Buy rating on Agile Therapeutics today and set a price target of $4. The company’s shares closed yesterday at $0.96.

Livnat said:

“We believe this study, along with additional CMC information, should check all the boxes from the the FDA and allow the Twirla application to be properly evaluated in the context of its actual benefit-risk profile for women. We expect Agile to resubmit the NDA by 2Q19, possibly have an FDA Advisory Committee meeting, which we welcome and would expect a favorable vote, then be approved by 4Q19 after a 6-month review. We continue to believe Twirla is an important potential addition to the hormonal contraceptive armamentarium, with a benefit-risk profile likely better than high-dose, block-box labeled Xulane which does 1.7M Rx/year. We project peak Twirla sales of approximately $350M with just over 2% peak market share.”

According to TipRanks.com, Livnat is a 3-star analyst with an average return of 3.4% and a 51.6% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Verrica Pharmaceuticals Inc, Taiwan Liposome Company Ltd, and Pacira Pharmaceuticals.

Agile Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $3.50, a 266.1% upside from current levels. In a report issued on February 11, Maxim Group also maintained a Buy rating on the stock with a $3 price target.

TG Therapeutics (TGTX)

In a report released today, Edward White from H.C. Wainwright reiterated a Buy rating on TG Therapeutics, with a price target of $20. The company’s shares closed yesterday at $4.80, close to its 52-week low of $3.32.

White said:

“Our $20 price target is based on the net present value of our revenue forecast through 2027, applying a 40% probability of success (POS) for ublituximab in CLL, a 40% POS for umbralisib in CLL, a 25% POS for both ublituximab and umbralisib in 40% POS for ublituximab in MS. We use a 4x price/sales multiple for these products and an early stage pipeline value of $0.23/share, which includes an anti-PD-L1 drug, and oral BTK inhibitor, and a CD47/CD19 bi-specific antibody, to arrive at our price target. Our P/S multiple of 4x is in-line with TG’s peers that range between 2-5x.”

According to TipRanks.com, White is a 5-star analyst with an average return of 14.0% and a 46.2% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and Synthetic Biologics Inc.

Currently, the analyst consensus on TG Therapeutics is a Strong Buy with an average price target of $12.67, implying a 164.0% upside from current levels. In a report issued on February 6, Jefferies also initiated coverage with a Buy rating on the stock with a $8 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts